| Literature DB >> 22021872 |
Tetsuro Tsujimoto1, Hiroshi Kajio, Yoshihiko Takahashi, Miyako Kishimoto, Hiroshi Noto, Ritsuko Yamamoto-Honda, Munehiro Kamimura, Miyako Morooka, Kazuo Kubota, Takuro Shimbo, Michiaki Hiroe, Mitsuhiko Noda.
Abstract
BACKGROUND: Recent studies have suggested that microvascular and macrovascular diseases are associated with coronary events.Entities:
Year: 2011 PMID: 22021872 PMCID: PMC3211053 DOI: 10.1136/bmjopen-2011-000139
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow chart of study participants. CHD, coronary heart disease.
Characteristics of study population*
| N | All | Men | Women | |
| 122 | 84 (69%) | 38 (31%) | ||
| Age (years) | 122 | 64.1 (8.3) | 63.9 (8.3) | 64.6 (8.5) |
| Weight (kg) | 122 | 64.6 (12.4) | 66.7 (12.1) | 60.1 (12.2) |
| Body-mass index (kg/m2) | 122 | 24.5 (4.0) | 24.3 (3.7) | 25.1 (4.5) |
| Waist (cm) | 112 | 90.3 (11.2) | 89.8 (10.7) | 91.5 (12.5) |
| Smoking | 122 | |||
| Non | 47 (39%) | 16 (18%) | 31 (82%) | |
| Former | 37 (30%) | 34 (41%) | 3 (8%) | |
| Current | 38 (31%) | 34 (41%) | 4 (10%) | |
| History of cerebrovascular disease | 122 | 46 (37%) | 32 (38%) | 14 (36%) |
| Duration of diabetes (years) | 122 | 16.0 (10.2) | 16.5 (9.8) | 15.2 (11.1) |
| Age (years) at the time of diabetes diagnosis | 122 | 49.0 (12.2) | 48.4 (11.8) | 50.4 (13.1) |
| Any diabetic retinopathy | 122 | 97 (79%) | 67 (79%) | 30 (79%) |
| Proliferative diabetic retinopathy or after photocoagulation | 122 | 76 (62%) | 50 (59%) | 26 (68%) |
| A1C (%) | 122 | 7.7 (1.5) | 7.8 (1.7) | 7.5 (1.2) |
| Treatment for diabetes | 122 | |||
| Diet | 7 (6%) | 7 (8%) | 0 (0%) | |
| Oral agents | 59 (48%) | 37 (44%) | 22 (58%) | |
| Insulin | 15 (12%) | 13 (16%) | 2 (5%) | |
| Insulin+oral agents | 41 (34%) | 21 (32%) | 14 (37%) | |
| Hypertension | 122 | 95 (77%) | 66 (78%) | 29 (76%) |
| Treatment | ||||
| Angiotensin II receptor blockers/angiotensin-converting enzyme inhibitors | 88 (72%) | 61 (72%) | 27 (71%) | |
| Calcium-channel blockers | 55 (45%) | 37 (44%) | 18 (47%) | |
| Diuretics | 16 (13%) | 9 (10%) | 7 (18%) | |
| Others | 4 (3%) | 3 (3%) | 1 (2%) | |
| Dyslipidaemia | 122 | 90 (73%) | 60 (71%) | 30 (79%) |
| Total cholesterol (mg/dl) | 192.7 (39.0) | 194.7 (42.4) | 188.3 (30.9) | |
| LDL cholesterol (mg/dl) | 115.6 (40.5) | 119.6 (43.8) | 106.5 (30.4) | |
| HDL cholesterol (mg/dl) | 52.4 (14.8) | 51.1 (13.5) | 55.3 (17.2) | |
| Triglyceride (mg/dl) | 143.3 (85.9) | 142.7 (86.1) | 144.6 (86.7) | |
| LDL/HDL ratio | 2.4 (1.1) | 2.5 (1.1) | 2.2 (0.9) | |
| Treatment | ||||
| Statin | 47 (38%) | 25 (29%) | 22 (57%) | |
| Others | 9 (7%) | 7 (8%) | 2 (5%) | |
| Use of aspirin | 122 | 33 (27%) | 23 (27%) | 10 (26%) |
| Creatinine (mg/dl) | 120 | 1.04 (0.60) | 1.08 (0.60) | 0.94 (0.60) |
| Estimated glomerular filtration rate (ml/min/1.73 m2) | 120 | 62.1 (22.0) | 63.3 (20.4) | 59.7 (25.4) |
| <45 | 28 (23%) | 17 (20%) | 11 (28%) | |
| <30 | 10 (8%) | 5 (6%) | 5 (13%) | |
| Use of haemodialysis | 2 | 2 (1%) | 2 (2%) | 0 (0%) |
| Albuminuria (mg/day or mg/g of creatinine) | 117 | |||
| <30 | 32 (27%) | 16 (20%) | 16 (45%) | |
| 30–299 | 40 (34%) | 28 (34%) | 12 (33%) | |
| ≥300 | 45 (39%) | 37 (46%) | 8 (22%) | |
| Renal dysfunction | 122 | 25 (20%) | 17 (20%) | 8 (21%) |
| Brain natriuretic peptide (pg/ml) | 113 | 37.2 (26.1 to 48.2) | 19.4 (7.5 to 47.5) | 24.8 (11 to 39.8) |
| Rest ECG | ||||
| Any abnormal findings | 122 | 27 (22%) | 19 (22%) | 8 (21%) |
| Abnormal Q wave changes | 3 (2%) | 2 (2%) | 1 (2%) | |
| Ischaemic findings on exercise stress ECG | 64 | 25 (39%) | 15 (36%) | 10 (43%) |
| Cardiothoracic ratio on chest x-ray (%) | 113 | 48.0 (4.4) | 47.6 (4.5) | 48.9 (4.0) |
| Ankle–brachial index | 122 | 1.07 (0.17) | 1.06 (0.18) | 1.09 (0.17) |
| Brachial–ankle pulse wave velocity (cm/s) | 108 | 2012.2 (377.3) | 1940.5 (300.3) | 2168.3 (474.8) |
| Peripheral arterial disease | 122 | 21 (17%) | 17 (20%) | 4 (10%) |
| Echocardiography | ||||
| Ejection fraction (%) | 108 | 67.3 (8.6) | 66.4 (9.5) | 69.4 (6.0) |
| Septal+posterior wall thickness (mm) | 108 | 21.2 (3.4) | 21.3 (3.4) | 20.9 (3.4) |
| >25 | 10 (9%) | 6 (8%) | 4 (11%) | |
| E/A ratio | 107 | 0.76 (0.21) | 0.77 (0.17) | 0.75 (0.28) |
| Deceleration time (ms) | 107 | 236.4 (59.1) | 232.6 (60.5) | 244.6 (56.0) |
| E/E′ ratio | 96 | 11.3 (3.4) | 11.0 (2.86) | 12.1 (4.35) |
| Abnormal wall motion | 108 | 6 (5%) | 6 (8%) | 0 (0%) |
| Ultrasound of carotid artery | 81 | |||
| Maximum carotid intima-media thickness (mm) | 1.78 (1.07) | 1.97 (1.13) | 1.39 (0.86) | |
| ≥1.1 | 53 (67%) | 41 (77%) | 12 (46%) | |
| Coronary artery calcium scores (Agatston units) | 83 | 216.8 (52.0 to 602.7) | 300.4 (65.6 to 1201.2) | 110.9 (0 to 275.8) |
To convert the values for cholesterol and triglycerides to millimoles per litre (mmol/l), multiply by 0.02586 and 0.01129, respectively.
Data are number, number (%), mean (SD) or median (IQR).
Body-mass index was calculated as the weight in kilograms divided by the square of height in metres.
Cerebrovascular disease was defined as stroke or transient ischaemic attack.
Oral agents for the treatment of diabetes included metformin, sulfonylureas, thiazolidinediones, meglitinides and alpha-glucosidase inhibitors.
Hypertension was defined as a systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or the use of antihypertensive medication.
Dyslipidaemia was defined as low-density lipoprotein (LDL) ≥140 mg/dl, high-density lipoprotein (HDL) <40 mg/dl, or the use of lipid-lowering drug.
Renal dysfunction was defined as the estimated glomerular filtration rate <30 ml/min/1.73 m2 or the estimated glomerular filtration rate <45 ml/min/1.73 m2 plus albuminuria, which was ≥30 mg/day or ≥30 mg/g of creatinine.
E/A ratio was the ratio of the peak Doppler velocities of early to late diastolic flow in the mitral inflow. E/E′ ratio was the ratio of the peak Doppler velocities of early in the mitral inflow to the early diastolic velocity at the septal mitral annulus.
Figure 2Prevalence of myocardial perfusion abnormalities and asymptomatic coronary heart disease (CHD) (A). Prevalence of asymptomatic CHD for each of the vascular complications (B). Prevalence of asymptomatic CHD in patients with ischaemia or scar (C). Coronary artery calcium (CAC) scores in patients with or without asymptomatic CHD (D). PAD, peripheral arterial disease; PDR, proliferative diabetic retinopathy.
Analyses of clinical variables for asymptomatic coronary heart disease
| Univariate analysis | |||
| Variable | Asymptomatic coronary heart disease (+) | Asymptomatic coronary heart disease (−) | p Value |
| 59 (53%) | 53 (47%) | ||
| Men | 51 (86%) | 26 (49%) | <0.001 |
| Age (years) | 62.4 (8.8) | 65.3 (7.7) | 0.07 |
| Weight (kg) | 65.3 (12.9) | 64.7 (12.7) | 0.79 |
| Body-mass index (kg/m2) | 24.0 (3.4) | 25.3 (4.6) | 0.08 |
| Waist (cm) | 90.0 (11.4) | 91.1 (11.9) | 0.60 |
| Current smoker | 26 (44%) | 10 (18%) | 0.004 |
| History of cerebrovascular disease | 22 (37%) | 21 (39%) | 0.80 |
| Duration of diabetes (years) | 16.7 (10.5) | 14.9 (10.0) | 0.34 |
| Age (years) at the time of diabetes diagnosis | 46.7 (12.2) | 51.4 (11.9) | 0.04 |
| Any diabetic retinopathy | 46 (78%) | 42 (79%) | 0.86 |
| Proliferative diabetic retinopathy or after photocoagulation | 36 (61%) | 34 (64%) | 0.73 |
| A1C (%) | 7.3 (1.5) | 7.4 (1.6) | 0.76 |
| Use of insulin | 33 (55%) | 21 (39%) | 0.08 |
| Hypertension | 46 (78%) | 40 (75%) | 0.75 |
| Dyslipidaemia | 45 (76%) | 39 (73%) | 0.74 |
| Total cholesterol (mg/dl) | 192.8 (38.4) | 196.0 (39.5) | 0.67 |
| Low-density lipoprotein cholesterol (mg/dl) | 113.0 (36.6) | 120.0 (38.5) | 0.33 |
| High-density lipoprotein cholesterol (mg/dl) | 50.7 (13.7) | 53.5 (15.7) | 0.32 |
| Triglyceride (mg/dl) | 151.5 (89.0) | 136.6 (82.3) | 0.36 |
| Low-density lipoprotein/high-density lipoprotein ratio | 2.4 (1.0) | 2.4 (1.0) | 0.85 |
| Use of statin | 21 (35%) | 22 (41%) | 0.52 |
| Use of aspirin | 16 (27%) | 15 (28%) | 0.88 |
| Creatinine (mg/dl) | 1.03 (0.60) | 0.87 (0.35) | 0.09 |
| Glomerular filtration rate (ml/min/1.73 m2) | 63.9 (20.7) | 65.2 (20.0) | 0.74 |
| <45 | 13 (22%) | 9 (17%) | 0.50 |
| <30 | 2 (3%) | 3 (5%) | 0.56 |
| Albuminuria ≥30 (mg/day or mg/g of creatinine) | 43 (76%) | 32 (62%) | 0.11 |
| Brain natriuretic peptide (pg/ml) | 20.7 (7.6 to 35.4) | 17.4 (9.5 to 42.9) | 0.99 |
| Rest ECG | |||
| Ischaemic findings on exercise stress ECG | 12 (41%) | 10 (35%) | 0.66 |
| Cardio thoracic ratio on chest x-ray (%) | 47.3 (4.4) | 48.8 (4.1) | 0.08 |
| Ankle–brachial index | 1.06 (0.20) | 1.06 (0.15) | 0.98 |
| Brachial–ankle pulse wave velocity (cm/s) | 1955.3 (306.4) | 2067.4 (448.7) | 0.14 |
| Peripheral arterial disease | 12 (22%) | 8 (16%) | 0.42 |
| Echocardiography | |||
| Ejection fraction (%) | 65.6 (9.1) | 69.0 (8.0) | 0.04 |
| Septal wall+posterior wall thickness (mm) | 20.8 (3.7) | 21.2 (3.0) | 0.55 |
| E/A ratio | 0.81 (0.16) | 0.71 (0.24) | 0.02 |
| Deceleration time (ms) | 225.7 (58.2) | 247.5 (61.9) | 0.07 |
| E/E′ ratio | 10.8 (3.3) | 11.8 (3.2) | 0.15 |
| Abnormal wall motion | 4 (7%) | 2 (4%) | 0.47 |
| Ultrasound of carotid artery | |||
| Maximum carotid intima-media thickness (mm) | 2.11 (1.30) | 1.41 (0.70) | 0.005 |
| ≥1.1 | 28 (75%) | 20 (55%) | 0.07 |
| Coronary artery calcium scores (Agatston units) | 349.8 (99.6 to 1229.1) | 133.2 (0.0 to 359.0) | 0.003 |
Data are number (%), mean (SD), median (IQR), OR, or 95% CI. To convert the values for cholesterol and triglycerides to millimoles per litre (mmol/l), multiply by 0.02586 and 0.01129, respectively.